ApoCIII has both indirect atherogenic effects (it causes hypertriglyceridemia) and direct atherogenic effects (it stimulates monocyte adhesion to endothelial cells, promotes the production of inflammatory mediators in these cells, and increases LDL retention in the arterial wall) [38,39]. Here, APOC3 is linked to hypertriglyceridemia.